Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era

Since December 2019, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing global health emergency [1]. Elderly patients affected by chronic heart disease showed a high mortality risk in the setting of COVID-19 interstitial pneumonia [2,3]. This study aimed to assess if pharmacological cardio-active treatment reduce mortality risk in the setting of COVID-19 interstitial pneumonia.